title: Therapeutic alternatives for subacute peripheral arterial occlusion. Comparison by outcome, length of stay, and hospital charges.
abstract: Thrombolytic therapy using streptokinase or urokinase has been shown to be a viable alternative to surgical thrombectomy in patients with subacute peripheral arterial occlusion. Urokinase is associated with higher success and lower complication rates than streptokinase, but the cost of urokinase is at least seven times higher. To address questions of utility and effectiveness in the treatment of subacute peripheral arterial occlusions, the authors designed a retrospective study of patients treated either by surgical thrombectomy (n = 70), thrombolysis with streptokinase (n = 19), or thrombolysis with urokinase (n = 22). Outcome of therapy, length of hospital stay, and total hospital charges in the three groups were examined. Treatment successes in the three groups, defined as complete clearing of the occluded segment with patency maintained for 60 days, were 76% for thrombectomy, 32% for streptokinase, and 64% for urokinase. Total duration of hospitalization was 21.1, 21.3, and 11.5 days (P less than .05), respectively. Mean charges for thrombolytic agents were $690 for streptokinase and $6429 for urokinase. Mean total hospital charges, however, were $25,978 for streptokinase, $22,203 for urokinase, and $25,336 for thrombectomy (P = NS). The higher cost of urokinase, then, accounted for the similar total charges, despite the shortened length of stay. These results suggest that urokinase is cost-effective compared to streptokinase for subacute peripheral arterial occlusion. Compared to thrombectomy, thrombolysis with urokinase has a marginally lower patency rate at 60 days, but a significantly shorter length of hospital stay.
authors.affiliation: Department of Pharmacy Services, Brigham and Women's Hospital, Boston, Massachusetts.
authors.forename: J E
authors.initials: JE
authors.lastname: Janosik
authors.forename: M A
authors.initials: MA
authors.lastname: Bettmann
authors.forename: A F
authors.initials: AF
authors.lastname: Kaul
authors.forename: P F
authors.initials: PF
authors.lastname: Souney
mesh_terms: D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D005251:Fees, Medical; D006801:Humans; D007902:Length of Stay / Q000191:economics*; D016491:Peripheral Vascular Diseases / Q000453:epidemiology / Q000628:therapy*; D012189:Retrospective Studies; D013300:Streptokinase / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000191:economics*; D013927:Thrombosis / Q000453:epidemiology / Q000628:therapy*; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
chemical_list: D013300:Streptokinase; D014568:Urokinase-Type Plasminogen Activator